Dietary polyunsaturated fatty acids and incidence of end-stage renal disease in the Southern Community Cohort Study

Rakesh Malhotra¹,5, Kerri L. Cavanaugh¹,2, William J. Blot³,4, T. Alp Ikizler¹,2†, Loren Lipworth²,3*,† and Edmond K. Kabagambe²,3†

Abstract

Background: Whether polyunsaturated fatty acids (PUFA) are associated with end-stage renal disease (ESRD) in populations with a high burden of risk factors for kidney disease is unknown. We sought to determine whether PUFA intake is associated with ESRD.

Methods: We conducted a nested case–control study of ESRD within the Southern Community Cohort Study (SCCS), a prospective cohort of low-income blacks and whites in the southeastern US (2002–2009). Through 2012, 1,074 incident ESRD cases were identified by linkage with the United States Renal Data System and matched to 3,230 controls by age, sex and race. Dietary intake of total, n-3 or n-6 PUFA was assessed from a validated food frequency questionnaire administered at baseline. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed from logistic regression models that included matching variables, body mass index, smoking, diabetes, hypertension, education, income, total energy intake and percent energy from protein and saturated fat.

Results: The mean (SD) age of participants was 55 (9) years. Most participants were women (55%), black (87%), with hypertension (67%) and on average obtained 8% of their energy from PUFA. Higher PUFA intake was marginally associated with a lower risk of ESRD in adjusted analyses. The adjusted odds ratios (95% confidence intervals) for ESRD for the 5th vs. 1st quintile of PUFA were 0.79 (0.60–1.05; P \text{trend} = 0.06) for total PUFA, 0.81 (0.61–1.06; P \text{trend} = 0.04) for n-6 PUFA and 0.93 (0.71–1.21; P \text{trend} = 0.45) for n-3 PUFA.

Conclusions: We observed a marginally significant inverse trend between dietary PUFA intake and ESRD incidence, mainly driven by n-6 fatty acid intake. Our findings require replication but suggest that a diet rich in n-6 PUFA may prevent ESRD development in a population with a high burden of kidney disease risk factors.

Keywords: End-stage renal disease, Polyunsaturated fatty acids

Background

End-stage renal disease (ESRD) is major cause of morbidity and mortality [1–4] in the United States and other countries. While several studies have established diabetes and hypertension as strong risk factors for development of chronic kidney disease (CKD) and progression to ESRD [5–8], modifiable lifestyle factors such as diet may also be important contributors. Over the past decade, results from experimental and clinical studies have provided evidence that higher intake of polyunsaturated fatty acids (PUFA) is associated with lower risk of hypertension [9], diabetes progression [10] and in some [7, 11–15] but not all [15–17] studies, with a lower risk of developing CKD and its progression to ESRD. Most studies enrolled primarily affluent populations and had relatively small sample sizes, limiting their generalizability to lower socioeconomic populations who tend to have lower PUFA intake and a heavy burden of risk factors for kidney disease.

While most studies on PUFA and kidney diseases have focused on n-3 fatty acids [15], numerous large human
studies have shown that dietary or tissue levels of n-6 PUFA are inversely associated with inflammation [18–24] and with clinical events such as blood pressure, diabetes, and cardiovascular diseases (CVD) [25, 26], conditions that predispose to or complicate ESRD. In the Nurses’ Health Study (n = 83,349 women) [27], the hazard ratio (HR) (95 % confidence interval) for all-cause mortality was 0.85 (0.81–0.89) when comparing the top to the lowest quintile of n-6 PUFA. The corresponding HR for CVD mortality was 0.89 (0.85–0.94). An inverse association with mortality was also observed for arachidonic acid, the n-6 PUFA previously thought to lead to more pro-inflammatory products than anti-inflammatory products (HR = 0.90; 95 % CI: 0.85–0.94). Studies that aim to understand the distinct contributions of n-3 and n-6 fatty acids are important because these fatty acid series and their subtypes vary in their biological potencies. For instance, in our previous studies with erythrocyte fatty acids, n-6 fatty acid levels showed stronger inverse associations with lipids, blood pressure and markers of insulin resistance than n-3 fatty acids [28]. Others have also shown differences between n-6 and n-3 fatty acids in relation to markers of inflammation, with consistent reduction in inflammation observed for n-6 fatty acids [29]. Similarly, in hemodialysis patients, benefits on inflammation and mortality are observed for n-6 but not n-3 fatty acids [15]. Despite inconsistencies in the associations between n-3 and n-6 fatty acids with inflammation and kidney disease, some studies have reported benefits on kidney function from both n-3 and n-6 fatty acids [14].

Current dietary guidelines for the general population recommend substituting trans- and saturated fatty acids with PUFA [30] partly because of the beneficial effects of PUFA on blood pressure and blood lipid profiles [31, 32]. However, with only limited large population data on the relation between dietary fat and kidney diseases, Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for nutrition in CKD have not included specific dietary fatty acid intake recommendations for the prevention or management of kidney diseases [33].

In the present study, nested in a large prospective cohort of 86,000 low-income blacks and whites with a high burden of kidney disease risk factors, we sought to determine whether total intake of PUFA is associated with incidence of ESRD and whether the association varied by type of PUFA consumed (i.e., n-3 vs. n-6-PUFA). We have previously shown that the age-adjusted incidence rate of ESRD in this cohort, with 329,003 person-years of follow-up through 2012, was 214 per 100,000 person-years [34]. We hypothesized that higher intake of PUFA will be associated with a lower risk of ESRD and that both n-3 and n-6 fatty acids would be associated with a lower risk of ESRD.

Methods

The Southern Community Cohort Study

The sample for this nested case–control study was derived from individuals enrolled in the Southern Community Cohort Study (SCCS). The SCCS is a large ongoing population-based prospective cohort study examining health disparities among 86,000 black and white men and women, age 40–79, from 12 southeastern states (Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia) enrolled between 2002 and 2009. Approximately 86 % of participants were recruited in-person from one of the participating community health centers (CHC), which provide primary health care for low-income and under-insured populations [35, 36], while the remaining 14 % were recruited from the general population by mail. The current analysis was restricted to CHC-enrollees, which ensured that participants were of similar socioeconomic status and had generally equal access to health care at cohort entry regardless of race. Detailed description of SCCS methods has been previously published and is available on the study website (http://www.southerncommunitystudy.org) [38]. All participants provided written informed consent, and the study was approved by Institutional Review Boards of Vanderbilt University Medical Center and Meharry Medical College. We adhered to the guidelines and methodology set forth in the STrengthening the Reporting of OBservational studies in Epidemiology Statement [38].

Study population

All incident cases of ESRD among SCCS participants were identified by linking the cohort with the US Renal Data System (USRDS), which registers ESRD cases certified by a physician diagnosis and filed using a medical evidence report form (to the Medicare ESRD program) or when there is other evidence of chronic dialysis or a kidney transplant irrespective of the glomerular filtration rate (GFR) [39]. The data linkage spanned from January 1, 2002 to September 1, 2012, the latest date for which data were available, and since USRDS is a nationwide registry, there is near complete ascertainment of ESRD cases. SCCS participants who had a diagnosis of ESRD recorded in the USRDS prior to SCCS enrollment were excluded from our analyses [34]. Three controls were individually matched to each incident ESRD case by age at cohort enrollment (±5-year categories), sex and race.

Risk factor assessment

At enrollment in SCCS, CHC participant characteristics including demographic variables, socioeconomic status, medical history, and lifestyle attributes (e.g., smoking and physical activity) were assessed using a standardized computer-assisted personal interview (questionnaire
Dietary intake was assessed at baseline using a validated food frequency questionnaire [35]. Estimates for nutrient intakes were calculated by utilizing sex- and race-specific nutrient databases derived from government food consumption surveys in the southern US [35, 40]. The overall diet questionnaire has been extensively validated in the SCCS and other populations; while not specifically validated for PUFA, intakes of PUFA in the SCCS participants are similar to those of the general US population, as shown in our previous publications [37, 40].

Statistical analyses
From the 4,788 participants in the age-, sex- and race-matched ESRD nested case–control study we excluded 484 individuals with missing data on covariates, leaving 1,074 incident ESRD cases and 3,230 controls for the final analyses. Since some of the case–control matches were broken because of missing data, to maximize use of data, we used methods for unmatched data while accounting for matching variables as covariates.

To reduce confounding by total energy intake, we expressed protein, saturated fat, monounsaturated fat and polyunsaturated fat intakes as percentages of daily energy intake and adjusted for daily total energy intake in the models. Next we tested whether the distributions of participant characteristics differed significantly by case–control status using the chi-square test for categorical variables and unpaired t-test for continuous variables. We further computed descriptive statistics for potential confounders by categories of major ESRD risk factors, namely hypertension and diabetes.

We then distributed participants into quintiles of energy intake from total, n-3 and n-6 PUFA and used unconditional logistic regression to estimate odds ratios (OR) and 95 % confidence intervals (CI) for the relation between intake of PUFAs and ESRD. For models with total, n-3 or n-6 PUFA intake as the independent variable, we adjusted for matching variables (age, sex and race), important predictors of ESRD in our cohort such as diabetes (yes or no) and hypertension (yes or no), as well as body mass index (BMI, kg/m²), continuous), education (< high school vs. high school or higher), income (< $ 15,000 vs. higher), smoking status (current and past vs. never), total energy intake and % energy from protein and saturated fat as continuous variables. For total, n-3 and n-6 PUFA variables, we computed median percent energy intake for each quintile and assigned it to all participants in a given quintile of the respective PUFA variable. The resulting continuous variable was added to the logistic regression model to obtain the p-value for trend.

In a subset of the study sample for whom baseline serum creatinine measurements were available, we conducted sensitivity analyses to examine whether baseline kidney function confounded the association between PUFA intake and ESRD. We performed logistic regression analyses in a subgroup of 1,574 participants with eGFR ≥ 60 mL/min/1.73 m² at baseline. These analyses included 180 incident ESRD cases. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). P-values ≤ 0.05 were considered statistically significant.

Results
The characteristics of ESRD cases and controls are shown in Table 1. The age, sex and race distributions of cases and controls were similar given the matched design (54.6 ± 9.0 vs 54.6 ± 8.8 years, 54.8 vs 55.4 % women, and 86.3 vs 86.9 % black, respectively). Participants in the SCCS who subsequently developed ESRD were more likely to have history of diabetes (63.9 vs 23.0 %; P < 0.0001) and hypertension (84.2 vs 61.3 %; P < 0.0001). Compared to controls, ESRD cases were also likely to have higher BMI (31.8 ± 8.2 vs 30.3 ± 7.2; P < 0.0001) and a household income of < $15,000 (68.5 vs 59.7 %; P < 0.0001).

Table 2 shows baseline dietary characteristics of study participants stratified by diabetes, hypertension and ESRD status. Individuals with diabetes reported consuming significantly more protein and PUFA as a percent of total energy than those without diabetes (P < 0.0001). Among participants with diabetes but without hypertension, both total and n-6 PUFA intake were lower among ESRD cases than controls but the differences in other groups were not pronounced. Regardless of hypertension status, ESRD cases with diabetes had lower dietary fiber intakes than

| Variable                              | ESRD cases (n = 1,074) | Controls (n = 3,230) | P   |
|---------------------------------------|------------------------|----------------------|-----|
| Age at enrollment, years*             | 54.6 ± 9.0             | 54.6 ± 8.8           | –   |
| Sex, % women*                         | 54.8                   | 55.4                 | –   |
| Race, % black*                        | 86.3                   | 86.9                 | –   |
| Body mass index, kg/m²                | 31.8 ± 8.2             | 30.3 ± 7.2           | <0.0001 |
| Smoking status, %                     |                        |                      | 0.13|
| Current smoker                        | 37.6                   | 40.9                 |     |
| Past smoker                           | 26.6                   | 24.3                 |     |
| Never smoker                          | 35.8                   | 34.7                 |     |
| Education < high school, %            | 37.0                   | 34.4                 | 0.13|
| Household income < $15,000/year, %   | 68.5                   | 59.7                 | <0.0001|
| History of hypertension, % yes        | 84.2                   | 61.3                 | <0.0001|
| History of diabetes, % yes            | 63.9                   | 23.0                 | <0.0001|

Abbreviations: ESRD end-stage renal disease
Continuous variables are expressed as mean ± SD and categorical variables as percentage (%)
*Matching variable
individuals with diabetes but without ESRD. The stratified
groups were similar with regard to dietary carbohydrate,
saturated fatty acids (SFAs), mono-unsaturated fatty acid
(MUFAs) and fiber intake (Table 2).

As shown in Table 3, median intakes for n-3 PUFA
were low while median total and n-6 PUFA intakes
were similar to those of the general US population
(about 8 % of energy). In the final adjusted multivari-
able logistic regression models, we observed marginally
significant modest inverse associations between total
PUFA and n-6 PUFA and ESRD incidence. For instance,
the adjusted ORs (95 % CIs) for ESRD for the 5th vs. 1st
quintile of PUFA were 0.79 (0.60–1.05; \( P_{\text{trend}} = 0.06 \)) for
total PUFA and 0.81 (0.61–1.06; \( P_{\text{trend}} = 0.04 \)) for n-6
PUFA. Although the OR estimates for n-3 PUFA were
in the same direction as those for total and n-6 PUFA,
there was no evidence for an inverse trend between n-3
PUFA and ESRD incidence (OR = 0.93; 95 % CI: 0.71–
1.21; \( P_{\text{trend}} = 0.45 \)) (Table 3).

**Discussion**

In the current prospective study among black and white
men and women of generally low socioeconomic status
and with a high burden of risk factors for kidney disease,
we have demonstrated that higher intake of PUFA,
specifically n-6 PUFA, is associated with a modestly lower
incidence of ESRD independent of established risk factors
such as diabetes and hypertension.

Prior observational studies have reported a protectiv-
effect of dietary PUFA intake on renal dysfunction
[13, 14]. In the Blue Mountains Eye Study, Gopinath
et al. showed that a diet rich in n-3 PUFA was signifi-
cantly associated with reduced likelihood of having
CKD (i.e., having a GFR <60 mL/min per 1.73 m 2;a d-
justed OR = 0.87; 95 % CI: 0.76–0.99) among 2,600
participants aged > 49 years [13]. Similarly, in the
InCHIANTI (Aging in the Chianti Area) study of over
931 participants aged \( \geq 65 \) years, researchers found an
inverse association between total plasma PUFA levels
and age-associated decline in renal function, during 3-
year follow up [14]. In addition, they showed an in-
verse relation between total plasma PUFA and urine
protein excretion [14]. Meta-analyses examining the
effect of fish-oil in CKD secondary to IgA nephropa-
thy, diabetic nephropathy and/or systemic lupus ery-
thematosus showed reduction in albumin excretion
and a trend towards slowing rate of decline in GFR
[16]. In the Alpha Omega trial, long-term supplemen-
tation with the n-3 fatty acids eicosapentaenoic acid
and docosahexaenoic acid provided beneficial effects on
kidney function among patients with a history of myocar-
dial infarction [41]. Among renal transplant patients, high
levels of plasma marine n-3 PUFA have been associated
with reduced risk of graft loss [42], and supplementation
with an n-3 PUFA-rich diet showed reduction of systemic
inflammation and proteinuria [43].

**Table 2** Characteristics of end-stage renal disease cases and controls from the Southern Community Cohort Study by hypertension
and diabetes

|                      | No hypertension | No diabetes | No ESRD | Hypertension | No diabetes | No ESRD |
|----------------------|-----------------|-------------|---------|--------------|-------------|---------|
| **N**                | 91              | 1112        | 79      | 139          | 297         | 1374    |
| **Age at enrollment, y** | 49.8 ± 8.4     | 51.6 ± 8.4  | 54.6 ± 9.3 | 54.3 ± 7.9  | 54.6 ± 9.7  | 55.5 ± 8.4 |
| **Sex, % women**     | 36.3            | 46.5        | 65.8    | 54.7         | 43.4        | 57.6    |
| **Race, % black**    | 82.4            | 85.2        | 86.1    | 87.1         | 89.2        | 87.6    |
| **Smoking, % current** | 72.5           | 51.4        | 31.7    | 38.1         | 48.8        | 39.9    |
| **Body mass index, kg/m²** | 27.0 ± 6.0     | 27.6 ± 6.2  | 30.8 ± 7.0 | 31.7 ± 7.0  | 30.2 ± 8.0  | 30.8 ± 7.2 |
| **Total energy, kcal/d** | 3358 ± 1737    | 2810 ± 1559 | 2313 ± 1344 | 2429 ± 1379 | 2693 ± 1473 | 2516 ± 1384 |
| **Carbohydrate, % energy** | 49.0 ± 8.6     | 48.7 ± 8.8  | 50.0 ± 9.5 | 48.9 ± 9.0  | 49.8 ± 10.0 | 50.2 ± 9.2 |
| **Protein, % energy** | 14.8 ± 3.0      | 14.7 ± 3.0  | 16.1 ± 3.1 | 15.9 ± 3.6  | 14.8 ± 3.2  | 14.9 ± 3.0 |
| **MUFA, % energy**   | 13.0 ± 2.4      | 13.0 ± 2.6  | 12.8 ± 2.7 | 13.4 ± 2.9  | 12.8 ± 2.7  | 12.7 ± 2.7 |
| **SFA, % energy**    | 10.0 ± 1.9      | 10.1 ± 2.2  | 10.1 ± 2.3 | 10.3 ± 2.3  | 10.0 ± 2.3  | 9.9 ± 2.3  |
| **PUFA, % energy**   | 7.8 ± 1.7       | 7.9 ± 1.7   | 7.8 ± 1.8 | 8.5 ± 2.0   | 7.8 ± 1.7   | 7.9 ± 1.8  |
| **N3-PUFA, % energy** | 0.07 ± 0.09     | 0.06 ± 0.07 | 0.08 ± 0.07 | 0.07 ± 0.07 | 0.07 ± 0.09 | 0.07 ± 0.07 |
| **N6-PUFA, % energy** | 7.5 ± 1.6       | 7.6 ± 1.7   | 7.6 ± 1.7 | 8.2 ± 2.0   | 7.5 ± 1.6   | 7.6 ± 1.7  |
| **Dietary fiber, g/d** | 25.7 ± 14.5     | 22.5 ± 13.5 | 20.6 ± 11.9 | 22.7 ± 13.0 | 21.9 ± 13.0 | 21.3 ± 12.9 |

Abbreviations: ESRD End-stage renal disease, MUFA Monounsaturated fatty acids, SFA Saturated fatty acids, PUFA Polyunsaturated fatty acids
Continuous variables are expressed as mean ± SD and categorical variables as percentage (%)
Table 3  Odds ratios and 95% confidence intervals for the associations between total, n-6 and n-3 polyunsaturated fatty acids and incident end-stage renal disease in a case–control study nested within the Southern Community Cohort Study

| Fatty acid | Quintiles a | 1 (Lowest) | 2 | 3 | 4 | 5 (Highest) | P for trend |
|------------|-------------|------------|---|---|---|-------------|-------------|
| Total PUFA | ESRD cases  | 208 | 207 | 233 | 212 | 214 | |
|            | Median, % energy | 5.8 | 7.1 | 8.0 | 8.8 | 10.2 | |
|            | Model 1 | 1.00 | 1.00 (0.80–1.25) | 1.18 (0.95–1.47) | 1.04 (0.83–1.30) | 1.04 (0.84–1.31) | 0.63 |
|            | Model 2 | 1.00 | 0.94 (0.73–1.20) | 0.99 (0.77–1.27) | 0.80 (0.62–1.04) | 0.76 (0.59–0.99) | 0.02 |
|            | Model 3 b | 1.00 | 0.94 (0.73–1.21) | 1.01 (0.78–1.32) | 0.85 (0.65–1.12) | 0.79 (0.60–1.05) | 0.06 |
| n-6 PUFA   | ESRD cases  | 205 | 217 | 235 | 206 | 211 | |
|            | Median, % energy | 5.62 | 6.89 | 7.70 | 8.52 | 9.79 | |
|            | Model 1 | 1.00 | 1.08 (0.87–1.35) | 1.22 (0.98–1.52) | 1.02 (0.82–1.28) | 1.04 (0.84–1.31) | 0.88 |
|            | Model 2 | 1.00 | 1.02 (0.80–1.31) | 1.02 (0.79–1.31) | 0.80 (0.62–1.04) | 0.78 (0.60–1.01) | 0.01 |
|            | Model 3 b | 1.00 | 1.02 (0.80–1.32) | 1.03 (0.80–1.34) | 0.85 (0.64–1.11) | 0.81 (0.61–1.06) | 0.04 |
| n-3 PUFA   | ESRD cases  | 223 | 204 | 207 | 208 | 232 | |
|            | Median, % energy | 0.01 | 0.03 | 0.05 | 0.08 | 0.15 | |
|            | Model 1 | 1.00 | 0.89 (0.72–1.11) | 0.91 (0.73–1.13) | 0.91 (0.73–1.14) | 1.06 (0.85–1.32) | 0.66 |
|            | Model 2 | 1.00 | 0.90 (0.71–1.14) | 0.85 (0.67–1.08) | 0.86 (0.67–1.10) | 0.92 (0.71–1.19) | 0.38 |
|            | Model 3 b | 1.00 | 0.89 (0.70–1.14) | 0.85 (0.67–1.09) | 0.86 (0.67–1.11) | 0.93 (0.71–1.21) | 0.45 |

Abbreviations: ESRD End-stage renal disease, PUFA Polyunsaturated fatty acids

aValues are odds ratios and corresponding 95% confidence intervals from models in which total, n-6 and n-3 PUFA were modeled separately. Model 1 included matching variables (age, sex and race), total energy intake and quintiles of energy from total PUFA or n-3 PUFA or n-6 PUFA. Model 2 additionally adjusted for diabetes and percent energy from protein intake. Model 3 additionally adjusted for body mass index, hypertension, education level, household income, smoking status and percent energy from saturated fat intake.
bIn a sensitivity analysis among 1,574 participants with eGFR ≥60 mL/min/day (180 cases and 1394 controls), further adjusting for eGFR did not change the results appreciably. For example, in analyses adjusting for eGFR and covariates in model 3 and using the lowest quintile as the referent, the ORs (95% CIs) for ESRD in the 2nd, 3rd, 4th and 5th quintile of total PUFA were 0.90 (0.485, 1.69), 1.32 (0.71, 2.46), 1.44 (0.75, 2.75) and 0.90 (0.47, 1.74), respectively. The corresponding OR (95% CIs) for n-6 PUFA were 0.79 (0.42, 1.47), 1.26 (0.68, 2.30), 1.11 (0.58, 2.14) and 0.82 (0.43, 1.57) while they were 0.93 (0.53, 1.61), 0.55 (0.30, 1.02), 0.72 (0.40, 1.31) and 1.02 (0.56, 1.86) for n-3 PUFA.

In our study, we found a statistically significant trend for an inverse association between dietary n-6 PUFA intake and incidence of ESRD while a non-significant association was detected for n-3 PUFA. This observation for ESRD is in line with findings from a previous study in dialysis patients [15] in which dietary n-6 PUFA intake was associated with reduction in all-cause mortality but a null association was observed between n-3 PUFA and inflammation or mortality [15]. In the GO-FISH study, a single-center randomized, placebo-controlled, two-period crossover trial involving 29 adult diabetic patients with micro- or macroalbuminuria, 4 g/d of n-3 PUFA for 6 weeks showed a non-significant decrease in urinary albumin excretion (~7.2%; 95% CI −20.6 to 8.5; P = 0.35) and a significant effect on urine neutrophil gelatinase-associated lipocalin (NGAL) excretion (~16%; 95% CI −29.1 to −0.5%; P = 0.04) [44]. The investigators performed a subgroup analysis among patients on renin angiotensin aldosterone system (RAAS) inhibitors and found that n-3 PUFA supplementation had significant protective effects on multiple markers of kidney injury [44]. These data, though inconsistent, may suggest that n-6 PUFA and probably n-3 PUFA may contribute to both the development of ESRD and outcomes (e.g., CVD) of kidney diseases.

Dietary PUFA may be renoprotective through a variety of mechanisms. Literature from experimental studies suggests that high PUFA levels may preserve renal morphology by modifying kidney inflammatory and proliferative responses [18, 19, 45]. In vitro studies show that PUFA may decrease mesangial cell proliferation through reduced activity of platelet-derived growth factor [45]. The renoprotective effects of PUFA may also occur through reduction of inflammation since PUFA downregulate NF-κB, inhibit expression of leukocyte adhesion molecules and modify intrarenal and glomerular hemodynamics through decreased synthesis of renal prostaglandin like thromboxane A2 [18, 19]. Another plausible explanation for renoprotection is that adequate
levels of PUFA may reduce factors (e.g., blood pressure, oxidative stress, endothelial dysfunction and vascular calcification) that are involved in the pathogenesis of kidney diseases [25, 26].

The US Institute of Medicine of the National Academies of Science recommends that the daily dietary allowance for n-3 PUFA and n-6 PUFA be 0.6–1.2 % and 5–10 % of total energy intake, respectively [46]. Compared with these recommended intakes, PUFA intake in our study exceeds 9 % of energy only in the highest quintile of intake of n-6 and total PUFA, which could in part explain why the risk of ESRD was not reduced in the lower quintiles. No guidelines exist for dietary intake of PUFA in CKD/ESRD patients, and our results suggest a need for further evaluation of PUFA intake or blood levels in relation to kidney disease prevention and management, which may inform policy on whether it is important to include PUFA in dietary guidelines.

Our study has several strengths. First, the SCCS is a unique large population-based cohort comprising black and white participants of comparable low socioeconomic status and with a high burden of risk factors for kidney disease, a population not adequately represented in previous studies. Moreover, detailed information on ESRD risk factors, diet and confounders was obtained at baseline, and incident ESRD was ascertained using the USRDS for the entire cohort in a complete and systematic manner, thereby minimizing the possibility for selection bias. In addition, the questionnaire used to record dietary intake has been extensively validated in the SCCS population and other populations in the US [35, 40], and the study used energy-adjusted macronutrient variables, thus providing a more accurate estimate of the association between PUFA intake and ESRD.

There are, however, some limitations to our study. First, our study cannot prove causality and it is difficult to rule out residual confounding despite adjustment for several important confounders. As shown in analyses stratified by hypertension and diabetes, the distribution of common lifestyle variables was similar between ESRD cases and controls, suggesting that the impact of confounding by these variables is likely minimal. The relatively lower dietary n-3 PUFA intakes in SCCS participants may have precluded detecting its beneficial effect on renal function as postulated in other studies [13, 15]. Secondly, FFQ data were self-reported once at baseline and no updated dietary intakes were obtained so as to study effects of long-term, sustained PUFA intake. The questionnaire was not validated specifically for PUFA intake, and there could be reporting errors in the assessment of PUFA; however, they are likely to be minimal since, as we have shown in previous studies, estimated intakes of PUFA in the current study are similar to those of the general US population (~8 % of energy) reported from NHANES and other studies [47]. Our FFQ collected dietary history for the previous 12 months and it is possible that a participant’s diet at baseline may have changed during follow-up. Lastly, levels of serum creatinine as a marker of kidney function at baseline and/or follow up are only available for less than half of the study participants, thus precluding our ability to fully account for baseline differences in kidney function in our analyses. Nonetheless, the inverse association between PUFA intake and ESRD was still apparent after adjusting for eGFR in a subgroup with eGFR ≥60 mL/min/1.73 m².

Conclusions
We observed a marginally significant inverse trend between PUFA intake and ESRD incidence that was mainly driven by n-6 fatty acid intake. Our findings suggest that a diet rich in n-6 PUFA may prevent ESRD development in a population with a high burden of kidney disease risk factors. Further studies that use plasma or red blood cell membrane PUFA levels to determine their role in ESRD incidence and whether they confer survival benefits are needed. It is important to establish the optimal individual-level dietary n-3 and n-6 PUFA intakes for use as prophylactic or therapeutic strategies for kidney disease.

Abbreviations
BMI: Body mass index; CHC: Community health centers; CI: Confidence interval; CKD: Chronic kidney disease; CVD: Cardiovascular disease; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; FFQ: Food-frequency questionnaire; KDOQI: Kidney Disease Outcomes Quality Initiative; MDRD: Modification of Diet in Renal Disease; OR: Odds ratio; PUFA: Polyunsaturated-fatty acids; SCCS: Southern Community Cohort Study; USRDS: United States Renal Data System

Acknowledgements
None.

Funding
The SCCS, and the work of LL and WJB, was supported by grants from the National Cancer Institute (R01 CA092447) and the American Recovery and Reinvestment Act (3R01 CA092447-08S1) to WJB. We acknowledge additional support from the Department of Veterans Affairs (Wen Award # I01 CX000414 to TAI) and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK103935-01A1 to KLC). In addition, RM, KLC, TAI, LL and EKK were supported from institutional funds from the Vanderbilt Center for Kidney Disease and the Vanderbilt Epidemiology Center. The funding bodies had no role in study design, in collection, analysis or interpretation of data, in manuscript preparation, or in the decision to submit the manuscript for publication.

Availability of data and materials
Consistent with SCCS study operations, the dataset supporting the conclusions of this article is available upon approval by the SCCS Data and Biospecimen Use Committee. The SCCS has an open access policy for legitimate scientific purposes, but because of privacy concerns, requires Committee review of all data requests. All investigators are required to sign a data use agreement prior to receipt of SCCS study data that provides for: (1) Sharing of the data only with investigators signing the data use agreement and (2) Use of the data only for purposes approved by the Data and Biospecimen Use Committee. Prior to sharing of SCCS data for proposals approved by the Committee, datasets are de-identified according to the HIPAA Safe-Harbor Method (http://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/).
Authors’ contributions

Study concept and design: RM, TAI, LL, EKK. Data acquisition, analysis, or interpretation of data: RM, KLC, WJB, TAI, LL, EKK. Drafting of the manuscript: RM, TAI, LL, EKK. Critical revision of the manuscript for important intellectual content: KLC, WJB, TAI, LL, EKK. Statistical analysis: RM, LL, EKK. Obtained funding: TAI, WJB. Study supervision: WJB, TAI, LL, EKK. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. EKK, LL, RM and WJB had full access to all of the data in the study and take responsibility for the integrity of the data, the accuracy of the data analysis, and the honest, accurate and transparent reporting of the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

The authors declare that they have no competing interests.

Ethics approval and consent to participate

All participants provided written informed consent and, the study was approved by Institutional Review Boards of Vanderbilt University Medical Center and Meharry Medical College (IRB# 010345).

Author details

1Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. 2Division of Endocrinology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Ave, Suite 800, Nashville, TN 37203, USA. 3International Epidemiology Institute, Rockville, MD 20850, USA. 4Present address: Division of Nephropathy and Hypertension, University of California San Diego, San Diego, CA 92161, USA.

Received: 21 June 2016 Accepted: 11 October 2016

Published online: 18 October 2016

References

1. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. Clin J Am Soc Nephrol. 2006;11(7):1227–84.
2. Levey AS, Atkins R, Cored J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–9.
3. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–52.
4. Jha V, Garcia-Garcia G, Ito K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.
5. Kidokoro KO. DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154.
6. Kazancioglu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 2013;4(3):368–71.
7. Tsioulis C, Tatsis I, Thomopoulos C, et al. Effects of hypertension, diabetes mellitus, obesity and other factors on kidney haemodynamics. Curr Vasc Pharmacol. 2014;12(3):537–48.
8. Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015;22(2):388–95.
9. Yang B, Ding F, Yan J, et al. Explanatory serum fatty acid patterns associated with blood pressure in community-dwelling middle-aged and elderly Chinese. Lipids Health Dis. 2016;15(1):58.
10. Guerin N, Pirouetta L, Kerege A, Strauss A, Bergman BC. Dietary fatty acids differentially associate with fasting versus 2-hour glucose homeostasis; implications for the management of subtypes of prediabetes. PLoS One. 2016;11(3):e0150148.
11. Higashiyama A, Kubota Y, Marumo M, et al. Association between serum long-chain n-3 and n-6 polyunsaturated fatty acid profiles and glomerular filtration rate assessed by serum creatinine and cystatin C levels in Japanese community-dwellers. J Epidemiol. 2015;25(4):303–11.
12. Hsu CC, Jhang HR, Chang WT, et al. Associations between dietary patterns and kidney function indicators in type 2 diabetes. Clin Nutr. 2014;33(1):98–105.
13. Gopinath B, Harris DC, Flood VM, Burlaky G, Mitchell P. Consumption of long-chain n-3 PUFA, alpha-linolenic acid and fish is associated with the prevalence of chronic kidney disease. Br J Nutr. 2011;105(9):1361–8.
14. Lauretani F, Sembia RD, Bandinelli S, et al. Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem. 2008;54(3):475–81.
15. Huang X, Stenvinkel P, Qureshi AR, et al. Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. Nephrol Dial Transplant. 2012;27(9):3651–20.
16. Miller 3rd BR, Juraschek SP, Appel LJ, et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am J Clin Nutr. 2009;89(6):1937–45.
17. Huang X, Lindholm B, Stenvinkel P, Carrero JJ. Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. J Nephrol. 2013;26(6):960–74.
18. Grande JP, Walker-HU, Holub BJ, et al. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int. 2000;57(3):1027–40.
19. Chaudhary A, Mishra A, Sethi S. Oxidized omega-3 fatty acids inhibit pro-inflammatory responses in glomerular endothelial cells. Nephron Exp. 2004;97(4):136–145.
20. Perreault M, Roke K, Badawi A, et al. Plasma levels of 14:0, 16:0, 16:1n-7, and 20:3n-6 are positively associated, but 18:0 and 18:2n-6 are inversely associated with markers of inflammation in young healthy adults. Lipids. 2014;49(3):255–63.
21. Kaikkonen JE, Kesranov P, Ahotupa M, et al. High serum n6 fatty acid proportion is associated with lowered LDL oxidation and inflammation: the Cardiovascular Risk in Young Finns Study. Free Radic Res. 2014;48(4):420–6.
22. Sundaram S, Bukowsk MR, Lie WR, Picklo MI, Yan L. High-Fat diets containing different amounts of n3 and n6 polyunsaturated fatty acids modulate inflammatory cytokine production in mice. Lipids. 2016;51(5):71–82.
23. Wiese DM, Horst SN, Brown CT, et al. Serum fatty acids Are correlated with inflammatory cytokines in ulcerative colitis. PLoS One. 2016;11(5):e0156837.
24. Nyirenda CK, Kabagambe EE, Kothe JR, et al. Plasma fatty acids in Zambian adults with HIV/AIDS: relation to dietary intake and cardiovascular risk factors. J Nutr Metab. 2015;2015:563917.
25. Zhao G, Ethenord TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr. 2004;134(11):2991–7.
26. Egert S, Stehle P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care. 2011;14(2):121–31.
27. Wang QO, Li Y, Chiuve SE, et al. Association of specific dietary fats with total and cause-specific mortality. JAMA Intern Med. 2016;176(8):1134–45.
28. Kabagambe EE, Tsai MY, Hopkins PN, et al. Erythrocyte fatty acid composition and the metabolic syndrome: a National Heart, Lung, and Blood Institute GOLDN study. Clin Chem. 2005;51(1):154–62.
29. Muka T, Kieffer-de Jong JC, Hofman A, Dehghan A, Rivadeneira F, Franco OH. Polyunsaturated fatty acids and serum C-reactive protein: the Rotterdam study. Am J Epidemiol. 2015;181(11):846–56.
30. USDA and UDHHS. Report of the Dietary Guidelines Advisory Committee on the dietary guidelines for Americans. 2015.
31. Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015;19(3):441–5.
32. Morin C, Rousseau E, Blier PU, Fortin S. Effect of docosahexaenoic acid monoaoyglyceride on systemic hypertension and cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2015;309(1):H53–H102.
33. NKF-DOQI clinical practice guidelines for nutrition in chronic renal failure. American Journal of Kidney Diseases 2000;35(S2):S17-S104.
34. Lprim L, Murnma MT, Cavaunha KL, et al. Incidence and predictors of end stage renal disease among low-income blacks and whites. PLoS One. 2012(10)(e68407).
35. Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study: investigating health disparities. J Health Care Poor Underserved. 2010;21(1 Suppl):26–37.
36. Lipworth L, Fazio S, Kabagambe EE, et al. A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States. Clin Epidemiol. 2014:6:15–25.
37. Kiage JN, Sampson UK, Lipworth L, et al. Intake of polyunsaturated fat in relation to mortality among statin users and non-users in the Southern Community Cohort Study. Nutr Metab Cardiovasc Dis. 2015;25(11):1016–24.

38. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.

39. U S Renal Data System, USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2012.

40. Signorello LB, Munro HM, Buchowski MS, et al. Estimating nutrient intake from a food frequency questionnaire: incorporating the elements of race and geographic region. Am J Epidemiol. 2009;170(1):104–11.

41. Hoogeveen EK, Geleijnse JM, Kromhout D, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clin J Am Soc Nephrol. 2014;9(10):1676–83.

42. Eide IA, Jenssen T, Hartmann A, et al. Plasma levels of marine n-3 polyunsaturated fatty acids and renal allograft survival. Nephrol Dial Transplant. 2016;31(1):160–7.

43. Sabbatini M, Apicella L, Cataldi M, et al. Effects of a diet rich in N-3 polyunsaturated fatty acids on systemic inflammation in renal transplant recipients. J Am Coll Nutr. 2013;32(6):375–83.

44. Miller 3rd ER, Juraschek SP, Anderson CA, et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013;36(6):1462–9.

45. Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr. 2004;58(2):195–203.

46. Food and Nutrition Board IoMMaHD. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington: The National Academies Press; 2002. p. 609–96.

47. Kiage JN, Merrill PD, Robinson CJ, et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr. 2013;97(S):1121–8.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit